Mission
At Interface Bio, we are building a drug company at the frontier of innovation through the development of multi-targeted immunotherapies.
Complex diseases like autoimmune disorders and cancer require multi-mechanism therapies (e.g. ADCs, bi-specifics), but developing these drugs is challenging due to interaction effects, toxicity, and high costs. Interface Biosciences takes a different approach. Natural products produced and optimized by commensals in the human body are the world's best source of safe and effective therapeutics. Our platform leverages these chemical scaffolds using our AI-guided search strategies and optimization to generate next-generation immunotherapy assets at an unprecedented rate.
Technology
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Commensal microbes have coevolved with humans for millions of years, giving rise to a massive repertoire of non-toxic, bioactive, and multi-mechanism molecules. By combining precision culturomics, targeted metabolomics, molecular engineering, and AI, Interface Bio’s platform mines these natural product libraries to develop next generation, multi-mechanism therapeutics.
01
Build
We build libraries of microbial derived natural products that have a high potential for bioactivity. Our chemical libraries are curated from 1) Previously isolated microbial products that have not been tested for their potential as therapeutics and 2) Microbes grown up in culture with uncharacterized metabolites.
02
Screen
03
Optimize
04
Validate
Get in Touch
Reach out if you are interested in working with us or would like to learn more about how natural products could revolutionise the chemical space
